bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer
Authors: Qureshy Zoya , Li Hua , Zeng Yan , Rivera Jose , Cheng Ning , Peterson Christopher N. , Kim Mi-Ok , Ryan William R. , Ha Patrick K. , Bauman Julie E. , Wang Steven J. , Long Steven R. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

AbstractPurpose:
Increased activity of STAT3 is associated with progression of head and neck squamous cell carcinoma (HNSCC). Upstream activators of STAT3, such as JAKs, represent potential targets for therapy of solid tumors, including HNSCC. In this study, we investigated the anticancer effects of ruxolitinib, a clinical JAK1/2 inhibitor, in HNSCC preclinical models, including patient-derived xenografts (PDX) from patients treated on a window-of-opportunity trial.
Experimental Design:
HNSCC cell lines were treated with ruxolitinib, and the impact on activated STAT3 levels, cell growth, and colony formation was assessed. PDXs were generated from patients with HNSCC who received a brief course of neoadjuvant ruxolitinib on a clinical trial. The impact of ruxolitinib on tumor growth and STAT3 activation was assessed.
Results:
Ruxolitinib inhibited STAT3 activation, cellular growth, and colony formation of HNSCC cell lines. Ruxolitinib treatment of mice bearing an HNSCC cell line–derived xenograft significantly inhibited tumor growth compared with vehicle-treated controls. The response of HNSCC PDXs derived from patients on the clinical trial mirrored the responses seen in the neoadjuvant setting. Baseline active STAT3 (pSTAT3) and total STAT3 levels were lower, and ruxolitinib inhibited STAT3 activation in a PDX from a patient whose disease was stable on ruxolitinib, compared with a PDX from a patient whose disease progressed on ruxolitinib and where ruxolitinib treatment had minimal impact on STAT3 activation.
Conclusions:
Ruxolitinib exhibits antitumor effects in HNSCC preclinical models. Baseline pSTAT3 or total STAT3 levels in the tumor may serve as predictive biomarkers to identify patients most likely to respond to ruxolitinib.
Data from Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant
Authors: Wimberger Pauline , Gerber Mara Julia , Pfisterer Jacobus , Erdmann Kati , Füssel Susanne , Link Theresa , du Bois Andreas , Kommoss Stefan , Heitz Florian , Sehouli Jalid , Kimmig Rainer , de Gregorio Nikolaus , Schmalfeldt Barbara , Park-Simon Tjoung-Won , Baumann Klaus , Hilpert Felix , Grube Marcel , Schröder Willibald , Burges Alexander , Belau Antje , Hanker Lars , Kuhlmann Jan Dominik
Published: April 2023

AbstractPurpose:
The identification of a robust IHC marker to predict the response to antiangiogenic bevacizumab in ovarian cancer is of high clinical interest. VEGF-A, the molecular target of bevacizumab, is expressed as multiple isoforms with pro- or antiangiogenic properties, of which VEGF-A165b is the most dominant antiangiogenic isoform. The balance of VEGF-A isoforms is closely related to the angiogenic capacity of a tumor and may define its vulnerability to antiangiogenic therapy. We investigated whether the expression of VEGF-A165b could be related to the effect of bevacizumab in advanced ovarian cancer patients.
Experimental Design:
Formalin-fixed paraffin-embedded tissues from 413 patients of the ICON7 multicenter phase III trial, treated with standard platinum-based chemotherapy with or without bevacizumab, were probed for VEGF-A165b expression by IHC.
Results:
In patients with low VEGF-A165b expression, the addition of bevacizumab to standard platinum-based chemotherapy significantly improved progression-free (HR: 0.727; 95% CI, 0.538–0.984; P = 0.039) and overall survival (HR: 0.662; 95% CI, 0.458–0.958; P = 0.029). Multivariate analysis showed that the addition of bevacizumab in low VEGF-A165b–expressing patients conferred significant improvements in progression-free survival (HR: 0.610; 95% CI, 0.446–0.834; P = 0.002) and overall survival (HR: 0.527; 95% CI, 0.359–0.775; P = 0.001), independently from established risk factors.
Conclusions:
We demonstrate for the first time that bevacizumab may differentially improve the prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an antiangiogenic VEGF-A splice variant. We envision that this novel biomarker could be implemented into routine diagnostics and may have direct clinical implications for guiding bevacizumab-related treatment decisions in advanced ovarian cancer patients.
Data from Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation
Authors: Shouval Roni , Waters Nicholas R. , Gomes Antonio L. C. , Zuanelli Brambilla Corrado , Fei Teng , Devlin Sean M. , Nguyen Chi L. , Markey Kate A. , Dai Anqi , Slingerland John B. , Clurman Annelie G. , Fontana Emily , Amoretti Luigi A. , Wright Roberta J. , Hohl Tobias M. , Taur Ying , Sung Anthony D. , Weber Daniela , Hashimoto Daigo , Teshima Takanori , Chao Nelson J. , Holler Ernst , Scordo Michael , Giralt Sergio A. , Perales Miguel-Angel , Peled Jonathan U. , van den Brink Marcel R.M.
Published: April 2023

AbstractPurpose:
The gut microbiota is subject to multiple insults in allogeneic hematopoietic cell transplantation (allo-HCT) recipients. We hypothesized that preparative conditioning regimens contribute to microbiota perturbation in allo-HCT.
Experimental Design:
This was a retrospective study that evaluated the relationship between conditioning regimens exposure in 1,188 allo-HCT recipients and the gut microbiome. Stool samples collected from 20 days before transplantation up to 30 days after were profiled using 16S rRNA sequencing. Microbiota injury was quantified by changes in α-diversity.
Results:
We identified distinct patterns of microbiota injury that varied by conditioning regimen. Diversity loss was graded into three levels of conditioning-associated microbiota injury (CMBI) in a multivariable model that included antibiotic exposures. High-intensity regimens, such as total body irradiation (TBI)–thiotepa-cyclophosphamide, were associated with the greatest injury (CMBI III). In contrast, the nonmyeloablative regimen fludarabine–cyclophosphamide with low-dose TBI (Flu/Cy/TBI200) had a low-grade injury (CMBI I). The risk of acute GVHD correlated with CMBI degree. Pretransplant microbial compositions were best preserved with Flu/Cy/TBI200, whereas other regimens were associated with loss of commensal bacteria and expansion of Enterococcus.
Conclusions:
Our findings support an interaction between conditioning at the regimen level and the extent of microbiota injury.
Data from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Authors: Kinneer Krista , Wortmann Philipp , Cooper Zachary A. , Dickinson Niall J. , Masterson Luke , Cailleau Thais , Hutchinson Ian , Vijayakrishnan Balakumar , McFarlane Mary , Ball Kathryn , Davies Michael , Lewis Arthur , Huang Yue , Rosenbaum Anton I. , Yuan Jiaqi , Chesebrough Jon , Anderton Judith , Monks Noel , Novick Steven , Wang Jixin , Dimasi Nazzareno , Christie R. James , Sabol Darrin , Tosto Frances Anne , Wallez Yann , Leo Elisabetta , Albertella Mark R. , Staniszewska Anna D. , Tice David A. , Howard Philip W. , Luheshi Nadia , Sapra Puja
Published: April 2023

AbstractPurpose:
We evaluated the activity of AZD8205, a B7-H4–directed antibody–drug conjugate (ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination with the PARP1-selective inhibitor AZD5305, in preclinical models.
Experimental Design:
IHC and deep-learning–based image analysis algorithms were used to assess prevalence and intratumoral heterogeneity of B7-H4 expression in human tumors. Several TOP1i-ADCs, prepared with Val-Ala or Gly–Gly–Phe–Gly peptide linkers, with or without a PEG8 spacer, were compared in biophysical, in vivo efficacy, and rat toxicology studies. AZD8205 mechanism of action and efficacy studies were conducted in human cancer cell line and patient-derived xenograft (PDX) models.
Results:
Evaluation of IHC-staining density on a per-cell basis revealed a range of heterogeneous B7-H4 expression across patient tumors. This informed selection of bystander-capable Val-Ala–PEG8–TOP1i payload AZ14170133 and development of AZD8205, which demonstrated improved stability, efficacy, and safety compared with other linker–payload ADCs. In a study of 26 PDX tumors, single administration of 3.5 mg/kg AZD8205 provided a 69% overall response rate, according to modified RECIST criteria, which correlated with homologous recombination repair (HRR) deficiency (HRD) and elevated levels of B7-H4 in HRR-proficient models. Addition of AZD5305 sensitized very low B7-H4–expressing tumors to AZD8205 treatment, independent of HRD status and in models representing clinically relevant mechanisms of PARPi resistance.
Conclusions:
These data provide evidence for the potential utility of AZD8205 for treatment of B7-H4–expressing tumors and support the rationale for an ongoing phase 1 clinical study (NCT05123482).

See related commentary by Pommier and Thomas, p. 991
Data from Characterization of Cell-Free DNA Size Distribution in Osteosarcoma Patients
Authors: Udomruk Sasimol , Phanphaisarn Areerak , Kanthawang Thanat , Sangphukieo Apiwat , Sutthitthasakul Songphon , Tongjai Siripong , Teeyakasem Pimpisa , Thongkumkoon Patcharawadee , Orrapin Santhasiri , Moonmuang Sutpirat , Klangjorhor Jeerawan , Pasena Arnat , Suksakit Pathacha , Dissook Sivamoke , Puranachot Pitithat , Settakorn Jongkolnee , Pusadee Tonapha , Pruksakorn Dumnoensun , Chaiyawat Parunya
Published: April 2023

AbstractPurpose:
Cell-free DNA (cfDNA) analysis is a powerful tool for noninvasively predicting patient outcomes. We analyzed the size distribution of cfDNA and assessed its prognostic and diagnostic values in an osteosarcoma cohort.
Experimental Design:
The fragment size distribution and level of cfDNA were analyzed in 15 healthy donors and 50 patients with osteosarcoma using automated capillary electrophoresis. The prognostic performance of cfDNA size analysis was assessed using univariate and multivariable analyses. By performing whole-genome sequencing of matched cfDNA and osteosarcoma tissue samples, we investigated the correlation between the size and mutation profiles of cfDNA and the mutation concordance between cfDNA and paired tissue tumors.
Results:
The size of cfDNA fragments in patients with osteosarcoma was significantly shorter than in healthy donors, with the integrative analysis of size distribution and level of cfDNA achieving a high specificity and sensitivity of 100%. The short cfDNA fragment (150-bp cut-off) was an independent prognostic predictor in this osteosarcoma cohort [HR, 9.03; 95% confidence interval (CI), 1.13–72.20; P = 0.038]. Shortened cfDNA fragments were found to be a major source of mutations. Enrichment of cfDNA fragments with less than or equal to 150 bp by in silico size selection remarkedly improved the detection of copy-number variation signals up to 2.3-fold when compared with total cfDNA, with a higher concordance rate with matched osteosarcoma tissue.
Conclusions:
This finding demonstrated the potential of cfDNA size profiling in the stratification of poor prognostic patients with osteosarcoma. The short fragments of cfDNA are a promising source for boosting the detection of significant mutations in osteosarcoma.
Data from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Authors: Blandin Anne-Florence , Giglio Ross , Graham Maya Srikanth , Garcia Guadalupe , Malinowski Seth , Woods Jared K. , Ramkissoon Shakti , Ramkissoon Lori , Dubois Frank , Schoolcraft Kathleen , Tsai Jessica , Wang Dayle , Jones Robert , Vogelzang Jayne , Pelton Kristine , Becker Sarah , Watkinson Fiona , Sinai Claire , Cohen Elizabeth F. , Booker Matthew A. , Tolstorukov Michael Y. , Haemels Veerle , Goumnerova Liliana , Wright Karen , Kieran Mark , Fehnel Katie , Reardon David , Tauziede-Espariat Arnault , Lulla Rishi , Carcamo Benjamin , Chaleff Stanley , Charest Alain , De Smet Frederik , Ligon Azra H. , Dubuc Adrian , Pages Melanie , Varlet Pascale , Wen Patrick Y. , Alexander Brian M. , Chi Susan , Alexandrescu Sanda , Kittler Ralf , Bachoo Robert , Bandopadhayay Pratiti , Beroukhim Rameen , Ligon Keith L.
Published: April 2023

AbstractPurpose:
Anaplastic lymphoma kinase (ALK) aberrations have been identified in pediatric-type infant gliomas, but their occurrence across age groups, functional effects, and treatment response has not been broadly established.
Experimental Design:
We performed a comprehensive analysis of ALK expression and genomic aberrations in both newly generated and retrospective data from 371 glioblastomas (156 adult, 205 infant/pediatric, and 10 congenital) with in vitro and in vivo validation of aberrations.
Results:
ALK aberrations at the protein or genomic level were detected in 12% of gliomas (45/371) in a wide age range (0–80 years). Recurrent as well as novel ALK fusions (LRRFIP1–ALK, DCTN1–ALK, PRKD3–ALK) were present in 50% (5/10) of congenital/infant, 1.4% (3/205) of pediatric, and 1.9% (3/156) of adult GBMs. ALK fusions were present as the only candidate driver in congenital/infant GBMs and were sometimes focally amplified. In contrast, adult ALK fusions co-occurred with other oncogenic drivers. No activating ALK mutations were identified in any age group. Novel and recurrent ALK rearrangements promoted STAT3 and ERK1/2 pathways and transformation in vitro and in vivo. ALK-fused GBM cellular and mouse models were responsive to ALK inhibitors, including in patient cells derived from a congenital GBM. Relevant to the treatment of infant gliomas, we showed that ALK protein appears minimally expressed in the forebrain at perinatal stages, and no gross effects on perinatal brain development were seen in pregnant mice treated with the ALK inhibitor ceritinib.
Conclusions:
These findings support use of brain-penetrant ALK inhibitors in clinical trials across infant, pediatric, and adult GBMs.
Data from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
Authors: Jeon Seung Hyuck , Kang Minyong , Jeon Minwoo , Chung Youseung , Kim A Reum , Lee Yong Joon , Kim Eui-Soon , Nam Heejin , Park Junsik , Lee Jung-Yun , Shin Eui-Cheol , Seo Seong Il , Park Su-Hyung
Published: April 2023

AbstractPurpose:
Regulatory T cells (Tregs) exert immunosuppressive functions and hamper antitumor immune responses in the tumor microenvironment. Understanding the heterogeneity of intratumoral Tregs, and how it changes with tumor progression, will provide clues regarding novel target molecules of Treg-directed therapies.
Experimental Design:
From 42 patients with renal cell carcinoma and 5 patients with ovarian cancer, immune cells from tumor and peripheral blood were isolated. We performed multicolor flow cytometry and RNA-sequencing to characterize the phenotypes and heterogeneity of intratumoral Tregs. In vitro functional assays were performed to evaluate suppressive capacity of Tregs and effect of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)-mediated depletion. The CT26 tumor model was used to evaluate the association between intratumoral Tregs and tumor growth, and examine the in vivo role of CEACAM1+ intratumoral Tregs on antitumor immunity.
Results:
We found that CEACAM1 was selectively expressed on intratumoral Tregs, whereas its expression on peripheral Tregs or other immune cells was low. The CEACAM1+ intratumoral Tregs accumulated with tumor progression, whereas the CEACAM1− subset did not. Notably, we found that CEACAM1 marked intratumoral Tregs that exhibited highly suppressive and activated phenotypes with substantial clonal expansion. Depletion of CEACAM1-expressing cells from tumor-infiltrating leukocytes led to increased effector functions of tumor-infiltrating T cells. Moreover, CEACAM1+ cell depletion further enhanced anti-PD-1–mediated reinvigoration of exhausted CD8+ T cells.
Conclusions:
CEACAM1 marks highly suppressive subset of intratumoral Tregs, and can be a target for selective depletion of intratumoral Tregs. These results may inform future studies on CEACAM1-mediated depletion in patients with cancer.
Data from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Authors: Wei Fang , Su Yuling , Quan Yibo , Li Xiaojia , Zou Qi , Zhang Liuxi , Li Shu , Jiang Mengmeng , Lin Guohuan , Liang Ping , He Jie , Xie Keping
Published: April 2023

AbstractPurpose:
Pancreatic ductal adenocarcinoma (PDA) resists immunotherapy of adoptive cell transfer (ACT) and immune checkpoint inhibitors. Understanding the mechanisms underlying this resistance will improve PDA immunotherapy. This study investigated therapeutic effects and underlying mechanisms of anticoagulants on immunotherapy in PDA.
Experimental Design:
The antitumor activity of immunotherapy was evaluated in mouse models of desert, excluded, and inflamed tumors. The underlying mechanisms were investigated by analyzing immune cell infiltration by immunofluorescence imaging and tumor microcirculation by interstitial fluid pressure and coagulation status measurement.
Results:
Combined use of heparin and ACT inhibited tumor growth and metastasis, whereas neither heparin nor ACT had any therapeutic effect. The combination of heparin and ACT significantly increased the intratumor infiltration of CD8+ T cells and M1 macrophages and reduced the infiltration of immunosuppressive M2 macrophages and FOXP3+/CD4+ regulatory T cells (Treg). Assessments of tumor microenvironment revealed that heparin promoted tumor vascular regression and normalized the remaining blood vessels, facilitating the extravasation and perivascular accumulation of activated CD8+ T cells in tumors. Mechanistically, tumor microvessel hemodynamic properties were significantly improved by heparin, which is consistent with its inhibitory effects on tumor angiogenesis. Similarly, the combination of heparin and anti-PD1 also produced a pronounced antitumor activity, whereas neither heparin nor anti-PD1 treatment had appreciable antitumor activity.
Conclusions:
Combined treatment of heparin and ACT or anti-PD1 produced synergistic antitumor effects, which were at least in part through tumor vascular normalization, hence increased antitumor T-cell responses due to reduced Treg infiltration and increased M1 macrophage polarization. This synergistic combination therapy warrants clinical evaluation.

See related commentary by Korc, p. 2348
Supplementary Fig. S1 from Class I β-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions
Authors: Liaw Tracy Y.E. , Salam Noeris K. , McKay Matthew J. , Cunningham Anne M. , Hibbs David E. , Kavallaris Maria
Published: April 2023

Supplementary Fig. S1 from Class I β-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions
Supplementary Table S1 from Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Authors: Ma Jie , Waxman David J.
Published: April 2023

Supplementary Table S1 from Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Supplementary Fig. S3 from UA62784, a novel inhibitor of centromere protein E kinesin-like protein
Authors: Henderson Meredith C. , Shaw Yeng-Jeng Y. , Wang Hong , Han Haiyong , Hurley Laurence H. , Flynn Gary , Dorr Robert T. , Von Hoff Daniel D.
Published: April 2023

Supplementary Fig. S3 from UA62784, a novel inhibitor of centromere protein E kinesin-like protein
Supplementary Fig. S3 from A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Authors: Samaddar Julia S. , Gaddy Virgil T. , Duplantier Jennifer , Thandavan Sudharsan Periyasamy , Shah Manish , Smith Marlena J. , Browning Darren , Rawson Jim , Smith Sylvia B. , Barrett John T. , Schoenlein Patricia V.
Published: April 2023

Supplementary Fig. S3 from A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Supplementary Fig. S2 from A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Authors: Samaddar Julia S. , Gaddy Virgil T. , Duplantier Jennifer , Thandavan Sudharsan Periyasamy , Shah Manish , Smith Marlena J. , Browning Darren , Rawson Jim , Smith Sylvia B. , Barrett John T. , Schoenlein Patricia V.
Published: April 2023

Supplementary Fig. S2 from A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Supplementary Fig. S2 from Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
Authors: Pchejetski Dimitri , Doumerc Nicolas , Golzio Muriel , Naymark Maria , Teissié Justin , Kohama Takafumi , Waxman Jonathan , Malavaud Bernard , Cuvillier Olivier
Published: April 2023

Supplementary Fig. S2 from Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
Supplementary Figure 1C from Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
Authors: Jantscheff Peter , Schlesinger Martin , Fritzsche Juliane , Taylor Lenka A. , Graeser Ralph , Kirfel Gregor , Fürst Dieter O. , Massing Ulrich , Bendas Gerd
Published: April 2023

Supplementary Figure 1C from Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
Supplementary Figures and Table Legends from Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia
Authors: Chou C. James , Farkas Michelle E. , Tsai Sherry M. , Alvarez David , Dervan Peter B. , Gottesfeld Joel M.
Published: April 2023

Supplementary Figures and Table Legends from Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia
Supplementary Table S2 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Authors: Bataller Marc , Méndez Carmen , Salas José A. , Portugal José
Published: April 2023

Supplementary Table S2 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Supplementary Fig. S1 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Authors: Bataller Marc , Méndez Carmen , Salas José A. , Portugal José
Published: April 2023

Supplementary Fig. S1 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Supplementary Fig. S2 from Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status
Authors: Sedic Mirela , Poznic Miroslav , Gehrig Peter , Scott Mike , Schlapbach Ralph , Hranjec Marijana , Karminski-Zamola Grace , Pavelic Kresimir , Pavelic Sandra Kraljevic
Published: April 2023

Supplementary Fig. S2 from Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status
Supplementary from Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
Authors: Meng Yang , Tang Wenhua , Dai Yao , Wu Xiaoqing , Liu Meilan , Ji Qing , Ji Min , Pienta Kenneth , Lawrence Theodore , Xu Liang
Published: April 2023

Supplementary from Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
Supplementary Fig. S2 from The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis
Authors: Raja Shruti M. , Chen Shuzhen , Yue Ping , Acker Timothy M. , Lefkove Benjamin , Arbiser Jack L. , Khuri Fadlo R. , Sun Shi-Yong
Published: April 2023

Supplementary Fig. S2 from The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis
Supplementary Fig. S1 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Authors: Ackler Scott , Xiao Yu , Mitten Michael J. , Foster Kelly , Oleksijew Anatol , Refici Marion , Schlessinger Sally , Wang Baole , Chemburkar Sanjay R. , Bauch Joy , Tse Christin , Frost David J. , Fesik Stephen W. , Rosenberg Saul H. , Elmore Steven W. , Shoemaker Alex R.
Published: April 2023

Supplementary Fig. S1 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Supplementary Fig. S1 from Adenoviral endoplasmic reticulum–targeted mda-7/interleukin-24 vector enhances human cancer cell killing
Authors: Pataer Abujiang , Hu Wenxian , Xiaolin Lu , Chada Sunil , Roth Jack A. , Hunt Kelly K. , Swisher Stephen G.
Published: April 2023

Supplementary Fig. S1 from Adenoviral endoplasmic reticulum–targeted mda-7/interleukin-24 vector enhances human cancer cell killing
Supplementary Fig. from Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death
Authors: Little Joy L. , Wheeler Frances B. , Koumenis Constantinos , Kridel Steven J.
Published: April 2023

Supplementary Fig. from Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death
Supplementary Data from Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer
Authors: Distler Ute , Souady Jamal , Hülsewig Marcel , Drmić-Hofman Irena , Haier Jörg , Denz Axel , Grützmann Robert , Pilarsky Christian , Senninger Norbert , Dreisewerd Klaus , Berkenkamp Stefan , Schmidt M. Alexander , Peter-Katalinić Jasna , Müthing Johannes
Published: April 2023

Supplementary Data from Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer
Supplementary Table S7 from Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Authors: Song Dongweon , Chaerkady Raghothama , Tan Aik Choon , García-García Elena , Nalli Anuradha , Suárez-Gauthier Ana , López-Ríos Fernando , Zhang Xian Feng , Solomon Anna , Tong Jeffrey , Read Margaret , Fritz Christian , Jimeno Antonio , Pandey Akhilesh , Hidalgo Manuel
Published: April 2023

Supplementary Table S7 from Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Supplementary Table S3 from Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Authors: Song Dongweon , Chaerkady Raghothama , Tan Aik Choon , García-García Elena , Nalli Anuradha , Suárez-Gauthier Ana , López-Ríos Fernando , Zhang Xian Feng , Solomon Anna , Tong Jeffrey , Read Margaret , Fritz Christian , Jimeno Antonio , Pandey Akhilesh , Hidalgo Manuel
Published: April 2023

Supplementary Table S3 from Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Supplementary Figure 2B from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Authors: Hou Xiaonan , Huang Fei , Carboni Joan M. , Flatten Karen , Asmann Yan W. , Ten Eyck Cynthia , Nakanishi Takeo , Tibodeau Jennifer D. , Ross Douglas D. , Gottardis Marco M. , Erlichman Charles , Kaufmann Scott H. , Haluska Paul
Published: April 2023

Supplementary Figure 2B from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
Supplementary Fig. S3 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Authors: Mei Szu-Chieh , Wu Rong-Tsun
Published: April 2023

Supplementary Fig. S3 from The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Supplementary Data from A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes
Authors: Sung Eun-Sil , Park Kyung-Jin , Lee Seung-Hyun , Jang Yoon-Seon , Park Sang-Koo , Park Yoo-Hoi , Kwag Won-Jae , Kwon Myung-Hee , Kim Yong-Sung
Published: April 2023

Supplementary Data from A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes
Supplementary Data from TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis
Authors: Ashimori Naoki , Zeitlin Benjamin D. , Zhang Zhaocheng , Warner Kristy , Turkienicz Ilan M. , Spalding Aaron C. , Teknos Theodoros N. , Wang Shaomeng , Nör Jacques E.
Published: April 2023

Supplementary Data from TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis
Supplementary Fig. S4 from Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
Authors: Santarosa Manuela , Del Col Laura , Tonin Elena , Caragnano Angela , Viel Alessandra , Maestro Roberta
Published: April 2023

Supplementary Fig. S4 from Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
Supplementary Fig. S1 from Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
Authors: Santarosa Manuela , Del Col Laura , Tonin Elena , Caragnano Angela , Viel Alessandra , Maestro Roberta
Published: April 2023

Supplementary Fig. S1 from Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
Supplementary Data from A Bead-Based Activity Screen for Small-Molecule Inhibitors of Signal Transduction in Chronic Myelogenous Leukemia Cells
Authors: Sylvester Juliesta E. , Kron Stephen J.
Published: April 2023

Supplementary Data from A Bead-Based Activity Screen for Small-Molecule Inhibitors of Signal Transduction in Chronic Myelogenous Leukemia Cells
Supplementary Video 1 from The Dynamin Inhibitors MiTMAB and OcTMAB Induce Cytokinesis Failure and Inhibit Cell Proliferation in Human Cancer Cells
Authors: Joshi Sanket , Perera Swetha , Gilbert Jayne , Smith Charlotte M. , Mariana Anna , Gordon Christopher P. , Sakoff Jennette A. , McCluskey Adam , Robinson Phillip J. , Braithwaite Antony W. , Chircop Megan
Published: April 2023

Supplementary Video 1 from The Dynamin Inhibitors MiTMAB and OcTMAB Induce Cytokinesis Failure and Inhibit Cell Proliferation in Human Cancer Cells
Supplementary Figure 1 from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Authors: Lam Lloyd T. , Lu Xin , Zhang Haichao , Lesniewski Rick , Rosenberg Saul , Semizarov Dimitri
Published: April 2023

Supplementary Figure 1 from A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Supplementary Fig. from Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines
Authors: Kondo Eisaku , Tanaka Takehiro , Miyake Takayoshi , Ichikawa Tomotsugu , Hirai Masahiko , Adachi Masaki , Yoshikawa Kazuhiro , Ichimura Koichi , Ohara Nobuya , Moriwaki Akiyoshi , Date Isao , Ueda Ryuzo , Yoshino Tadashi
Published: April 2023

Supplementary Fig. from Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines
Supplementary Figures 1-3 from Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Authors: Kuo Wen-Liang , Liu Jing , Mauceri Helena , Vokes Everett E. , Weichselbaum Ralph , Rosner Marsha Rich , Cohen Ezra Eddy Wyssam
Published: April 2023

Supplementary Figures 1-3 from Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Supplementary Figure Legends from Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Authors: Kuo Wen-Liang , Liu Jing , Mauceri Helena , Vokes Everett E. , Weichselbaum Ralph , Rosner Marsha Rich , Cohen Ezra Eddy Wyssam
Published: April 2023

Supplementary Figure Legends from Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Supplementary Figure S1 from The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach
Authors: Jessen Katayoun A. , English Nicole M. , Yu Wang Jean , Maliartchouk Sergei , Archer Shannon P. , Qiu Ling , Brand Regina , Kuemmerle Jared , Zhang Han-Zhong , Gehlsen Kurt , Drewe John , Tseng Ben , Cai Sui Xiong , Kasibhatla Shailaja
Published: April 2023

Expression profile
Supplementary Data from ARC Synergizes with ABT-737 to Induce Apoptosis in Human Cancer Cells
Authors: Bhat Uppoor G. , Pandit Bulbul , Gartel Andrei L.
Published: April 2023

Supplementary Data from ARC Synergizes with ABT-737 to Induce Apoptosis in Human Cancer Cells
Supplementary Figure 1 from Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab
Authors: Liu Zhaofei , Liu Yan , Jia Bing , Zhao Huiyun , Jin Xiaona , Li Fang , Chen Xiaoyuan , Wang Fan
Published: April 2023

Supplementary Figure 1 from Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab
Supplementary Table S2 from Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1
Authors: Sullivan Richard , Graham Charles H.
Published: April 2023

Supplementary Table S2 from Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1
Supplementary Fig. S2 from Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1
Authors: Sullivan Richard , Graham Charles H.
Published: April 2023

Supplementary Fig. S2 from Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1
Supplementary Figure 3 from Dihydroartemisinin Induces Apoptosis by a Bak-Dependent Intrinsic Pathway
Authors: Handrick René , Ontikatze Teona , Bauer Kerstin-Daniela , Freier Florian , Rübel Amelie , Dürig Jan , Belka Claus , Jendrossek Verena
Published: April 2023

Supplementary Figure 3 from Dihydroartemisinin Induces Apoptosis by a Bak-Dependent Intrinsic Pathway
Supplementary Figure S2 from Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Authors: Banerjee Abhijit G. , Bhattacharyya Indraneel , Vishwanatha Jamboor K.
Published: April 2023

Supplementary Figure S2 from Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Significant genes list from Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Authors: Banerjee Abhijit G. , Bhattacharyya Indraneel , Vishwanatha Jamboor K.
Published: April 2023

Significant genes list from Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Supplementary Figure Legend from γ-Tocotrienol Promotes TRAIL-Induced Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase/p53–Mediated Upregulation of Death Receptors
Authors: Kannappan Ramaswamy , Ravindran Jayaraj , Prasad Sahdeo , Sung Bokyung , Yadav Vivek R. , Reuter Simone , Chaturvedi Madan M. , Aggarwal Bharat B.
Published: April 2023

Supplementary Figure Legend from γ-Tocotrienol Promotes TRAIL-Induced Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase/p53–Mediated Upregulation of Death Receptors
Supplementary Figure Legends 1-4 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Authors: Wood Tabitha E. , Dalili Shadi , Simpson Craig D. , Sukhai Mahadeo A. , Hurren Rose , Anyiwe Kika , Mao Xinliang , Suarez Saiz Fernando , Gronda Marcela , Eberhard Yanina , MacLean Neil , Ketela Troy , Reed John C. , Moffat Jason , Minden Mark D. , Batey Robert A. , Schimmer Aaron D.
Published: April 2023

Supplementary Figure Legends 1-4 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Supplementary Figure 3 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Authors: Wood Tabitha E. , Dalili Shadi , Simpson Craig D. , Sukhai Mahadeo A. , Hurren Rose , Anyiwe Kika , Mao Xinliang , Suarez Saiz Fernando , Gronda Marcela , Eberhard Yanina , MacLean Neil , Ketela Troy , Reed John C. , Moffat Jason , Minden Mark D. , Batey Robert A. , Schimmer Aaron D.
Published: April 2023

Supplementary Figure 3 from Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands
Supplementary Data from Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells
Authors: Zhu Xiaodong , Bidlingmaier Scott , Hashizume Rintaro , James C. David , Berger Mitchel S. , Liu Bin
Published: April 2023

Supplementary Data from Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells
Supplementary Fig. S2 from MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma
Authors: Marampon Francesco , Bossi Gianluca , Ciccarelli Carmela , Di Rocco Agnese , Sacchi Ada , Pestell Richard G. , Zani Bianca M.
Published: April 2023

Supplementary Fig. S2 from MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma
Supplementary Fig. S1 from MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma
Authors: Marampon Francesco , Bossi Gianluca , Ciccarelli Carmela , Di Rocco Agnese , Sacchi Ada , Pestell Richard G. , Zani Bianca M.
Published: April 2023

Supplementary Fig. S1 from MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma
Supplementary Figure 2 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma
Authors: Alfano Randall W. , Leppla Stephen H. , Liu Shihui , Bugge Thomas H. , Ortiz Janelle M. , Lairmore Terry C. , Duesbery Nicholas S. , Mitchell Ian C. , Nwariaku Fiemu , Frankel Arthur E.
Published: April 2023

Supplementary Figure 2 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma
Supplementary Fig. S1 from Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor
Authors: Mahmud Hayat , Dälken Benjamin , Wels Winfried S.
Published: April 2023

Supplementary Fig. S1 from Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor
Supplementary Table S3 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Authors: McDonagh Charlotte F. , Kim Kristine M. , Turcott Eileen , Brown Lindsay L. , Westendorf Lori , Feist Tiffany , Sussman Django , Stone Ivan , Anderson Martha , Miyamoto Jamie , Lyon Robert , Alley Stephen C. , Gerber Hans-Peter , Carter Paul J.
Published: April 2023

Supplementary Table S3 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Supplementary Table S1 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Authors: McDonagh Charlotte F. , Kim Kristine M. , Turcott Eileen , Brown Lindsay L. , Westendorf Lori , Feist Tiffany , Sussman Django , Stone Ivan , Anderson Martha , Miyamoto Jamie , Lyon Robert , Alley Stephen C. , Gerber Hans-Peter , Carter Paul J.
Published: April 2023

Supplementary Table S1 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Supplementary Material from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Authors: McDonagh Charlotte F. , Kim Kristine M. , Turcott Eileen , Brown Lindsay L. , Westendorf Lori , Feist Tiffany , Sussman Django , Stone Ivan , Anderson Martha , Miyamoto Jamie , Lyon Robert , Alley Stephen C. , Gerber Hans-Peter , Carter Paul J.
Published: April 2023

Supplementary Material from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Supplementary Fig. S2 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Authors: McDonagh Charlotte F. , Kim Kristine M. , Turcott Eileen , Brown Lindsay L. , Westendorf Lori , Feist Tiffany , Sussman Django , Stone Ivan , Anderson Martha , Miyamoto Jamie , Lyon Robert , Alley Stephen C. , Gerber Hans-Peter , Carter Paul J.
Published: April 2023

Supplementary Fig. S2 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Supplementary Table 1 from Curcumin Enhances the Effect of Cisplatin in Suppression of Head and Neck Squamous Cell Carcinoma via Inhibition of IKKβ Protein of the NFκB Pathway
Authors: Duarte Victor M. , Han Eugene , Veena Mysore S. , Salvado Amanda , Suh Jeffrey D. , Liang Li-Jung , Faull Kym F. , Srivatsan Eri S. , Wang Marilene B.
Published: April 2023

Supplementary Table 1 from Curcumin Enhances the Effect of Cisplatin in Suppression of Head and Neck Squamous Cell Carcinoma via Inhibition of IKKβ Protein of the NFκB Pathway
Supplementary Figure 1 from Preclinical Evaluation of Differentially Targeting Dual Virotherapy for Human Solid Cancer
Authors: Sakai Ryo , Kagawa Shunsuke , Yamasaki Yasumoto , Kojima Toru , Uno Futoshi , Hashimoto Yuuri , Watanabe Yuichi , Urata Yasuo , Tanaka Noriaki , Fujiwara Toshiyoshi
Published: April 2023

Supplementary Figure 1 from Preclinical Evaluation of Differentially Targeting Dual Virotherapy for Human Solid Cancer
Supplementary Video 3 from Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition
Authors: Reka Ajaya Kumar , Kurapati Himabindu , Narala Venkata R. , Bommer Guido , Chen Jun , Standiford Theodore J. , Keshamouni Venkateshwar G.
Published: April 2023

Supplementary Video 3 from Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition
Supplementary Data from PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation
Authors: Chang Marisa , Kanwar Nisha , Feng Eric , Siu Allan , Liu Xiujie , Ma Dawei , Jongstra Jan
Published: April 2023

Supplementary Data from PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation
Supplementary Data from Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
Authors: Duan Zhenfeng , Choy Edwin , Harmon David , Yang Cao , Ryu Keinosuke , Schwab Joseph , Mankin Henry , Hornicek Francis J.
Published: April 2023

Supplementary Data from Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
Supplementary Fig. S2 from Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
Authors: McGovern Ursula B. , Francis Richard E. , Peck Barrie , Guest Stephanie K. , Wang Jun , Myatt Stephen S. , Krol Janna , Kwok Jimmy M-M. , Polychronis Andreas , Coombes R. Charles , Lam Eric W-F.
Published: April 2023

Supplementary Fig. S2 from Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
Supplementary Figures 1-8 from Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth
Authors: Zhang Ping , Singh Anju , Yegnasubramanian Srinivasan , Esopi David , Kombairaju Ponvijay , Bodas Manish , Wu Hailong , Bova Steven G. , Biswal Shyam
Published: April 2023

Supplementary Figures 1-8 from Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth
Supplementary Figure 8 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Authors: Nagji Alykhan S. , Cho Sang-Hoon , Liu Yuan , Lee Jae K. , Jones David R.
Published: April 2023

Supplementary Figure 8 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Supplementary Figure 1 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Authors: Nagji Alykhan S. , Cho Sang-Hoon , Liu Yuan , Lee Jae K. , Jones David R.
Published: April 2023

Supplementary Figure 1 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Supplementary Fig. S1 from The antitumor properties of a nontoxic, nitric oxide–modified version of saquinavir are independent of Akt
Authors: Maksimovic-Ivanic Danijela , Mijatovic Sanja , Miljkovic Djordje , Harhaji-Trajkovic Ljubica , Timotijevic Gordana , Mojic Marija , Dabideen Darrin , Cheng Kai Fan , McCubrey James A. , Mangano Katia , Al-Abed Yousef , Libra Massimo , Garotta Gianni , Stosic-Grujicic Stanislava , Nicoletti Ferdinando
Published: April 2023

Supplementary Fig. S1 from The antitumor properties of a nontoxic, nitric oxide–modified version of saquinavir are independent of Akt
Supplementary Figure 1 from Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells
Authors: Moiseeva Elena P. , Almeida Gabriela M. , Jones George D.D. , Manson Margaret M.
Published: April 2023

PDF file, 67KB, MDA-MB- 231 cells were treated for 48 h with phytochemicals in indicated concentrations (μM).
Supplementary Figure 2 from Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
Authors: Nagaraj Nagathihalli S. , Smith J. Joshua , Revetta Frank , Washington M. Kay , Merchant Nipun B.
Published: April 2023

Supplementary Figure 2 from Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
Supplementary Figure 1 from Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
Authors: Lagas Jurjen S. , van Waterschoot Robert A.B. , Sparidans Rolf W. , Wagenaar Els , Beijnen Jos H. , Schinkel Alfred H.
Published: April 2023

Supplementary Figure 1 from Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
Supplementary Data from EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins
Authors: Winkler Johannes , Martin-Killias Patricia , Plückthun Andreas , Zangemeister-Wittke Uwe
Published: April 2023

Supplementary Data from EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins